QIAstat-Dx

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Mesoblast (ASX: MSB) clears key treatment milestone ahead of mid-2027 back pain trial readout

Santos (ASX: STO) warns Australia’s 20% gas reservation rule could undermine GLNG economics

Russian missiles strike Kyiv as attacks injure 17 in Zaporizhzhia and Kharkiv

Regis Resources (ASX: RRL) drops Vault Minerals bid, letting Genesis Minerals’s A$5.6bn offer proceed

Representative image of molecular diagnostics, market volatility, and leadership transition themes as Qiagen (NYSE: QGEN) approaches its new CEO appointment and Q1 2026 earnings, with investors closely watching QIAstat-Dx, QuantiFERON, and strategic review developments.

Qiagen (NYSE: QGEN) at a crossroads ahead of new CEO and Q1 2026 results

Qiagen (NYSE: QGEN) retail investor roadmap: strategic review, CEO search, 2026 product pipeline and what the May earnings call means for shareholders.

bySrinath

April 3, 2026

QIAGEN’s new Barcelona facility will drive innovation in infectious disease testing and precision medicine with its cutting-edge QIAstat-Dx system.

QIAGEN invests in new Barcelona facility to expand QIAstat-Dx capabilities

QIAGEN, a leading global provider of molecular diagnostics, has announced a multi-year investment in a new facility in…

byPallavi Madhiraju

November 28, 2024

The Latest

Mesoblast (ASX: MSB) clears key treatment milestone ahead of mid-2027 back pain trial readout

Santos (ASX: STO) warns Australia’s 20% gas reservation rule could undermine GLNG economics

Russian missiles strike Kyiv as attacks injure 17 in Zaporizhzhia and Kharkiv

Regis Resources (ASX: RRL) drops Vault Minerals bid, letting Genesis Minerals’s A$5.6bn offer proceed

Qiagen (NYSE: QGEN) at a crossroads ahead of new CEO and Q1 2026 results

QIAGEN invests in new Barcelona facility to expand QIAstat-Dx capabilities

Mesoblast (ASX: MSB) clears key treatment milestone ahead of mid-2027 back pain trial readout

Santos (ASX: STO) warns Australia’s 20% gas reservation rule could undermine GLNG economics

Russian missiles strike Kyiv as attacks injure 17 in Zaporizhzhia and Kharkiv

Regis Resources (ASX: RRL) drops Vault Minerals bid, letting Genesis Minerals’s A$5.6bn offer proceed

Henry Boot (LSE: BOOT) rises 7% after funding unlocks Golden Valley cyber campus

Anglo American wants to sell De Beers, so why is it turning off the taps at Venetia now?

Aditya Birla Renewables to buy Shell’s Sprng Energy in $1.8bn deal, doubling scale in India’s clean power race

Oxford Nanopore (LSE: ONT) retains 2026 guidance despite weaker first-half trading